NASDAQ: KLRS
Kalaris Therapeutics Inc Stock

$2.39-0.03 (-1.24%)
Updated Jul 18, 2025
KLRS Price
$2.39
Fair Value Price
$0.17
Market Cap
$44.70M
52 Week Low
$2.28
52 Week High
$24.15
P/E
-0.29x
P/B
0.7x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.61
Operating Cash Flow
-$31M
Beta
1.46
Next Earnings
Aug 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A

KLRS Overview

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine KLRS's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
KLRS
Ranked
Unranked of 476

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important KLRS news, forecast changes, insider trades & much more!

KLRS News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KLRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KLRS ($2.39) is overvalued by 1,310.5% relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KLRS ($2.39) is not significantly undervalued (1,310.5%) relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KLRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KLRS due diligence checks available for Premium users.

Valuation

KLRS fair value

Fair Value of KLRS stock based on Discounted Cash Flow (DCF)

Price
$2.39
Fair Value
$0.17
Overvalued by
1,310.50%
KLRS ($2.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KLRS ($2.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KLRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KLRS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.29x
Industry
-179.53x
Market
31.42x

KLRS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.7x
Industry
4.56x
KLRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KLRS's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.2M
Profit Margin
0%
KLRS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$103.1M
Liabilities
$39.2M
Debt to equity
0.61
KLRS's short-term assets ($102.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KLRS's short-term assets ($102.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KLRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KLRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.4M
Investing
$0.0
Financing
$107.3M
KLRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KLRS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
KLRS$44.70M-1.24%-0.29x0.70x
PEPGF$44.17M0.00%-0.43x0.48x
MRSN$43.99M-2.75%-0.60x-1.43x
PRLD$45.45M-1.83%-0.48x0.44x
OSTXD$46.08M-2.38%-1.91x-11.01x

Kalaris Therapeutics Stock FAQ

What is Kalaris Therapeutics's quote symbol?

(NASDAQ: KLRS) Kalaris Therapeutics trades on the NASDAQ under the ticker symbol KLRS. Kalaris Therapeutics stock quotes can also be displayed as NASDAQ: KLRS.

If you're new to stock investing, here's how to buy Kalaris Therapeutics stock.

What is the 52 week high and low for Kalaris Therapeutics (NASDAQ: KLRS)?

(NASDAQ: KLRS) Kalaris Therapeutics's 52-week high was $24.15, and its 52-week low was $2.28. It is currently -90.1% from its 52-week high and 4.82% from its 52-week low.

How much is Kalaris Therapeutics stock worth today?

(NASDAQ: KLRS) Kalaris Therapeutics currently has 18,702,418 outstanding shares. With Kalaris Therapeutics stock trading at $2.39 per share, the total value of Kalaris Therapeutics stock (market capitalization) is $44.70M.

Kalaris Therapeutics stock was originally listed at a price of $583.97 in Jul 30, 2020. If you had invested in Kalaris Therapeutics stock at $583.97, your return over the last 4 years would have been -99.59%, for an annualized return of -74.71% (not including any dividends or dividend reinvestments).

How much is Kalaris Therapeutics's stock price per share?

(NASDAQ: KLRS) Kalaris Therapeutics stock price per share is $2.39 today (as of Jul 18, 2025).

What is Kalaris Therapeutics's Market Cap?

(NASDAQ: KLRS) Kalaris Therapeutics's market cap is $44.70M, as of Jul 19, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kalaris Therapeutics's market cap is calculated by multiplying KLRS's current stock price of $2.39 by KLRS's total outstanding shares of 18,702,418.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.